Mutagenic Effects of Cisplatin the Sensitivity of Human Colon Cancer Cells to the Cytotoxic p 53 Modulates the Effect of Loss of DNA Mismatch Repair on Updated

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The Human Mutator Gene Homolog MSHP and Its Association with Hereditary Nonpolyposis Colon Cancer

  2003cited by this paper
• A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

  2000cited by this paper
• Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.

  2000cited by this paper
• Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair.

  1999cited by this paper
• Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT

  1999cited by this paper
• DNA repair, DNA replication, and UV mutagenesis.

  1999cited by this paper
• Disruption of p53 in human cancer cells alters the responses to therapeutic agents.

  1999influential reference
• DNA polymerase mutagenic bypass and proofreading of endogenous DNA lesions.

  1999cited by this paper
• Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.

  1999cited by this paper
• Human cells compromised for p53 function exhibit defective global and transcription-coupled nucleotide excision repair, whereas cells compromised for pRb function are defective only in global repair.

  1999cited by this paper
• The role of DNA mismatch repair in cisplatin mutagenicity.

  1999cited by this paper
• Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage.

  1999cited by this paper
• Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.

  1998cited by this paper
• The role of DNA mismatch repair in drug resistance.

  1998cited by this paper
• Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

  1998cited by this paper
• The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.

  1998cited by this paper
• The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.

  1998cited by this paper
• The Ability of a Variety of Polymerases to Synthesize Past Site-specific cis-syn, trans-syn-II, (6–4), and Dewar Photoproducts of Thymidylyl-(3′→5′)-thymidine*

  1998cited by this paper
• A novel plasmid shuttle vector for the detection and analysis of microsatellite instability in cell lines.

  1998cited by this paper
• Defective expression of the DNA mismatch repair protein, MLH1, alters G2-M cell cycle checkpoint arrest following ionizing radiation.

  1998cited by this paper
• Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard

  1997cited by this paper
• In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin.

  1997cited by this paper
• Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations.

  1996cited by this paper
• Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents.

  1996cited by this paper
• The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.

  1996cited by this paper
• The role of DNA mismatch repair in platinum drug resistance.

  1996cited by this paper
• Point mutations of the topoisomerase IIalpha gene in patients with small cell lung cancer treated with etoposide.

  1996cited by this paper
• Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2.

  1996cited by this paper
• Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).

  1996cited by this paper
• Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines.

  1995cited by this paper
• Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).

  1995cited by this paper
• p53 modulation of TFIIH–associated nucleotide excision repair activity

  1995cited by this paper
• Identification of mismatch repair genes and their role in the development of cancer.

  1995cited by this paper
• Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline.

  1995cited by this paper
• Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs.

  1994cited by this paper
• DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: implications for tolerance to DNA methylation damage.

  1994cited by this paper
• Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.

  1994cited by this paper
• Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells.

  1994cited by this paper
• Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis.

  1994cited by this paper
• Mutation of a mutL homolog in hereditary colon cancer.

  1994cited by this paper
• Mutator phenotypes in human colorectal carcinoma cell lines.

  1994cited by this paper
• An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.

  1993cited by this paper
• Hypermutability and mismatch repair deficiency in RER+ tumor cells.

  1993cited by this paper
• Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer.

  1993cited by this paper
• Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.

  1993cited by this paper
• Increased accumulation of p53 protein in cisplatin‐resistant ovarian cell lines

  1993cited by this paper
• Resistance to 1-beta-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene.

  1992cited by this paper
• Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53.

  1992cited by this paper
• In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene.

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper
• Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts.

  1988cited by this paper
• Cis-platinum(II) diamine dichloride causes mutation, transformation, and sister-chromatid exchanges in cultured mammalian cells.

  1979cited by this paper
• A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

  1979cited by this paper
• Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells.

  1978cited by this paper
• Radiation: Studies of Mouse Cells Lacking P53-mediated Dna Repair Responses to Uv

  year unknowncited by this paper

• No citing papers are available for this paper.